All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
With the submission of its new drug application for ruxolitinib, Incyte Corp. is counting on having the myelofibrosis field to itself for a few years with a first-in-class treatment.
